3 Stocks With Mouthwatering Dividends You Can Buy Right Now
How would you like to get paid every quarter (and sometimes every month) to own a stock? That's exactly what happens when you invest in dividend stocks. Sometimes, the amount you are paid to own these stocks can be very attractive.
Three Motley Fool contributors believe they've found stocks you can buy right now that have mouthwatering dividends. Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE).
A top dividend stock for the long haul
Prosper Junior Bakiny (AbbVie): Several factors make for an above-average dividend stock. AbbVie, a pharmaceutical company, checks many of those boxes. Consider the company's forward yield, which currently tops 3.5% versus the 1.3% average for the S&P 500. Although a stock can be attractive for dividends with a relatively low yield, income seekers often like juicy ones, and AbbVie's is.
We can also point to AbbVie's fantastic track record. The company is a Dividend King with an active streak of 53 consecutive payout increases. That suggests AbbVie is unlikely to slash its payouts anytime soon, as doing so would force the company to start the streak from scratch and maybe rejoin this exclusive club in another 50 years. Of course, AbbVie might be forced to cut its dividends if the business faces significant headwinds. However, that's yet another area where the company excels, which makes it a top dividend stock.
AbbVie is a leading drugmaker with a deep lineup of products that generate consistent revenue and earnings. Some of the company's medicines continue increasing their sales at a good clip. AbbVie's two biggest growth drivers are Skyrizi and Rinvoq, a pair of immunology medicines. These therapies have surprised even the company's management, which recently increased Skyrizi and Rinvoq's combined 2027 guidance by $4 billion to more than $31 billion.
AbbVie's lineup features several other key products, including its Botox franchise. And although it will face patent cliffs, as every drugmaker does, AbbVie also has a deep pipeline of investigational compounds that will eventually allow it to move beyond its current crop of therapies. All these things (and more) make AbbVie an attractive dividend stock. Income investors can safely add shares of the company to their portfolios and hold on to them for a long time.
Bristol Myers stock pays 5% and has underrated growth potential
David Jagielski (Bristol Myers Squibb): A dividend stock that income investors might want to consider loading up on right now is that of pharma giant Bristol Myers Squibb. It currently yields 5.1%, which is a higher-than-typical payout for this top healthcare company. At such a high yield, you may be concerned that it's unsustainable, but that's not the case.
The company's fundamentals are sound. In the trailing 12 months, Bristol Myers generated free cash flow totaling $13.1 billion, which is more than double the amount it has paid out in cash dividends during that stretch ($4.9 billion). In each of the past four years, Bristol Myers' free cash flow has totaled at least $11 billion.
The company has been struggling with growth in recent years due to rising competition and the loss of patent protection on key drugs. But its growth portfolio has been giving investors a reason to remain optimistic. Through the first three months of the year, its non-legacy products generated year-over-year growth of 18% when excluding foreign exchange.
Bristol Myers has been a solid name in healthcare for years, and while it's facing adversity, it's still growing. Last year, it obtained approval for schizophrenia drug Cobenfy, which may generate peak sales of up to $10 billion, according to some analysts.
At 18 times trailing earnings, this can be a great, cheap dividend stock to add to your portfolio today.
A safer dividend than initially meets the eye
Keith Speights (Pfizer): Investors are right to be at least somewhat skeptical when they see a stock with a super-high dividend yield. For example, Pfizer's forward dividend yield is 7.38%. Is a dividend cut on the way for the big pharmaceutical company? I don't think so.
Granted, Pfizer's dividend payout ratio of 122.5% might seem worrisome. However, the company generates enough free cash flow to cover its dividend at the current level. The amount of free cash flow could also increase as a result of Pfizer's cost-cutting initiatives. The drugmaker's dividend is safer than initially meets the eye, in my view.
I believe Pfizer's underlying business is also stronger than it might look at first glance. It's easy to focus only on the negatives. There are several, including a steep decline in COVID-19 product sales, some notable pipeline setbacks, the upcoming loss of exclusivity for multiple top-selling drugs, and the Trump administration's threats of tariffs on pharmaceutical imports.
But Pfizer has plenty of positives that offset those negatives. For one thing, I think its valuation more than reflects all the challenges, with shares trading at only 8 times forward earnings. The company also has several new products with fast-growing sales and a robust pipeline.
Should you invest $1,000 in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!*
Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 2, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
24 minutes ago
- CTV News
Lufa Farms partners with Walmart to grow and sell greenhouse produce
With Walmart Canada, Montreal's Lufa Farms will grow produce under a 127,000 square foot greenhouse roof. Lufa Farms partners with Walmart to grow and sell greenhouse produce A partnership involving Lufa Farms is giving buying local a whole new meaning. 'We want to use free space in the cities where the people are and live,' says Lionel Trombert, Lufa Farms vice-president of finance. With Walmart Canada, the food company is taking produce from local to hyperlocal under one 127,000 square foot greenhouse roof. 'Whatever is being grown here is being picked and harvested at night and given to our customers either through the Lufa websites and, in this case, through the Walmart kiosk downstairs on a fresh basis every morning,' Trombert says. From cucumbers to peppers, it's the first time Lufa Farms produce is being sold through a retailer. This is also the first time that Walmart Canada is selling produce from its own roof. On top of filling a demand to buy locally, the partnership is a solution that offers sustainability. Lufa Farms greenhouse Lufa Farms is teaming up with Walmart to grow produce under a 127,000 square foot greenhouse roof. (Anastasia Dextrene/CTV) 'Land and water have become scarce resources and hydroponic systems usually typically consumes only about 5 to 10 per cent of the water of a land farm,' says Trombert. Their site at Marché Central is pesticide-free and you won't find soil or dirt. Instead, you'll find a hydraulic system that's responsible for producing four tonnes of crops each day. The location was chosen as the perfect basis for the project's roots, due to its size and proximity to neighbourhoods. Walmart Canada market leader Jacinthe Langevin says the company purchased more than $3.8 billion worth of products from 460 Quebec retailers last year. 'We are so proud to add Lufa Farms officially to that list,' she said. The hope is that the project will keep growing. 'There's an ask from customers and we've experienced that when we first sold those products ... we sold out almost every day,' Langevin told CTV.
CTV News
26 minutes ago
- CTV News
Mike Johnson downplays Musk's influence and says Republicans will pass Trump's tax and budget bill
Speaker of the House Mike Johnson, R-La., wraps up a news conference on U.S. President Donald Trump's bill of tax breaks and spending cuts, at the Capitol in Washington, Wednesday, June 4, 2025. (AP Photo/J. Scott Applewhite) With an uncharacteristically feistiness, Speaker Mike Johnson took clear sides Sunday in U.S. President Donald Trump's breakup with mega-billionaire Elon Musk. The Republican House leader and staunch Trump ally said Musk's criticism of the GOP's massive tax and budget policy bill will not derail the measure, and he downplayed Musk's influence over the GOP-controlled Congress. 'I didn't go out to craft a piece of legislation to please the richest man in the world,' Johnson said on ABC's 'This Week.' 'What we're trying to do is help hardworking Americans who are trying to provide for their families and make ends meet,' Johnson insisted. Johnson said he has exchanged text messages with Musk since the former chief of Trump's Department of Government Efficiency came out against the GOP bill. Musk called it an 'abomination' that would add to U.S. debts and threaten economic stability. He urged voters to flood Capitol Hill with calls to vote against the measure, which is pending in the Senate after clearing the House. His criticism sparked an angry social media back-and-forth with Trump, who told reporters over the weekend that he has no desire to repair his relationship with Musk. The speaker was dismissive of Musk's threats to finance opponents — even Democrats — of Republican members who back Trump's bill. 'We've got almost no calls to the offices, any Republican member of Congress,' Johnson said. 'And I think that indicates that people are taking a wait and see attitude. Some who may be convinced by some of his arguments, but the rest understand: this is a very exciting piece of legislation.' Johnson argued that Musk still believes 'that our policies are better for human flourishing. They're better for the US economy. They're better for everything that he's involved in with his innovation and job creation and entrepreneurship.' The speaker and other Republicans, including Trump's White House budget chief, continued their push back Sunday against forecasts that their tax and budget plans will add to annual deficits and thus balloon a national debt already climbing toward $40 trillion. Johnson insisted that Musk has bad information, and the speaker disputed the forecasts of the nonpartisan Congressional Budget Office that scores budget legislation. The bill would extend the 2017 Trump tax cuts, cut spending and reduce some other levies but also leave some 10.9 million more people without health insurance and spike deficits by $2.4 trillion over the decade, according to the CBO's analysis. The speaker countered with arguments Republicans have made for decades: That lower taxes and spending cuts would spur economic growth that ensure deficits fall. Russell Vought, who leads the White House Office of Budget and Management, said on Fox News Sunday that CBO analysts base their models of 'artificial baselines.' Because the 2017 tax law set the lower rates to expire, CBO's cost estimates, Vought argued, presuming a return to the higher rates before that law went into effect. Vought acknowledged CBO's charge from Congress is to analyze legislation and current law as it is written. But he said the office could issue additional analyses, implying it would be friendlier to GOP goals. Asked whether the White House would ask for alternative estimates, Vought again put the burden on CBO, repeating that congressional rules allow the office to publish more analysis. Other Republicans, meanwhile, approached the Trump-Musk battle cautiously. 'As a former professional fighter, I learned a long time ago, don't get between two fighters,' said Oklahoma Sen. Markwayne Mullin on CNN's 'State of the Union.' He even compared the two billionaire businessmen to a married couple. 'President Trump is a friend of mine but I don't need to get, I can have friends that have disagreements,' Mullin said. 'My wife and I dearly love each other and every now and then, well actually quite often, sometimes she disagrees with me, but that doesn't mean that we can't stay focused on what's best for our family. Right now, there may be a disagreement but we're laser focused on what is best for the American people.' Bill Barrow, The Associated Press Associated Press journalist Gary Fields contributed from Washington.
CTV News
26 minutes ago
- CTV News
CTV QP: Boosting Canada's economy with domestic trade
Watch Internal Trade Minister Chrystia Freeland speaks about the significance of domestic trade and the impact it will have on Canada's economy.
